ASXL1 gene, Somatic mutations in the additional sex comb-like 1 (ASXL1), are involved in the regulation or recruitment of the Polycomb-group repressor complex (PRC) and trithorax-group (trxG) activator complex. Recently, ASXL1 gene profiling has been studied in various types of diseases, which is also considered as a novel marker which may be a risk factor related with the prevalence and prognostic of myelodysplastic syndromes, and may be used to determine with the prevalence and prognostic of myeloid leukemia. It has been described in various types of myeloid malignancies, including acute myeloid leukemia (1). More and more studies indicate that ASXL1 mutations are associated with a poor therapy outcome.
Cancer Type
Leukemia
Intended Use
Research Use Only